Malignant Pleural Mesothelioma So, what is mesothelioma? Malignant pleural mesothelioma is a very aggressive and almost always fatal type of cancer caused by exposure to Asbestos.…
The U.S. Food and Drug Administration has granted Humanitarian Use Device (HUD) status to Novocure‘s Tumor Treating Fields (TTFields) for treating pleural mesothelioma. The designation…
Workers who are exposed to asbestos early in their career are at higher risk of developing pleural mesothelioma (PM) than those who were exposed later…
Soluble mesothelin, a cell surface glycoprotein predominant in several types of cancer, is an independent prognostic marker and a new potential therapeutic target for patients…
Bristol-Myers Squibb is recruiting 600 participants into a global Phase 3 clinical trial investigating a combination of two immune checkpoint inhibitors — Opdivo (nivolumab) and…
Yondelis (trabectedin) stabilized a form of advanced mesothelioma that had progressed after earlier chemotherapy, according to a Phase 2 clinical trial in Italy. Researchers will…
Aduro Biotech has expanded its collaboration with Merck to include an additional Phase 2 trial to test a combination of Aduro’s immunotherapy, CRS-207, with Keytruda…
A Phase 3 British clinical trial will test whether the immune checkpoint inhibitor Opdivo (nivolumab) can help mesothelioma patients whose disease relapsed after platinum-based chemotherapy.…